Altimmune End-of-Phase 2 FDA Meet for Pemvidutide in Treatment of Obesity

 Company and Agency aligned on key efficacy and safety measures to be studied in Phase 3 program

Pivotal Phase 3 trials designed to leverage the differentiated attributes of pemvidutide and potential benefits of balanced GLP-1/glucagon dual agonism

https://www.globenewswire.com/news-release/2024/11/07/2976554/0/en/Altimmune-Announces-Successful-Completion-of-End-of-Phase-2-Meeting-with-FDA-for-Pemvidutide-in-the-Treatment-of-Obesity.html